| Previous Close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0450 x 0 |
| Ask | 0.0500 x 0 |
| Day's Range | 0.0450 - 0.0550 |
| 52 Week Range | 0.0450 - 0.2200 |
| Volume | 3,638,349 |
| Avg. Volume | 2,831,912 |
| Market Cap | 16.591M |
| Beta (3Y Monthly) | 3.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1320 |
| Earnings Date | Oct 22, 2018 - Oct 26, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.23 |
VANCOUVER , April 17, 2019 /CNW/ - Trading resumes in: Company: Kalytera Therapeutics Inc. TSX-Venture Symbol: KALY (All Issues) Resumption (ET): 1:30 PM IIROC can make a decision to impose a temporary ...
Kalytera Therapeutics, Inc. (the “Company”, or “Kalytera”) (KALY.V) (KALTF) announced today that it has filed a final short form prospectus (the “Final Prospectus”) with securities regulatory authorities in the provinces of Alberta, British Columbia and Ontario (and received a receipt therefor) in connection with its previously announced marketed offering of a minimum of 90,000,000 units of the Company (“Units”, or each a “Unit”) and a maximum of 200,000,000 Units for gross proceeds of $4,500,000 to $10,000,000 (the “Offering”). The first closing of the Offering is expected to occur on or about April 26, 2019, or such other date or dates as the Company and the Agents (as defined below) may agree (the “Closing Date”).
VANCOUVER , April 17, 2019 /CNW/ - The following issues have been halted by IIROC: Company: Kalytera Therapeutics Inc. TSX-Venture Symbol: KALY (all issues) Reason: At the Request of the Company Pending ...
Kalytera Therapeutics, Inc. (the “Company”, or “Kalytera”) (TSXV:KALY and OTCQB: KALTF) announced that it has filed a preliminary short form prospectus with the securities regulatory authorities in the provinces of Alberta, British Columbia and Ontario in connection with a proposed marketed offering of units of the Company (“Units”, or each a “Unit”) for gross proceeds of $4,500,000 to $10,000,000 (the “Offering”). Echelon Wealth Partners Inc. (the “Lead Agent”) and Paradigm Capital Inc. (collectively with the Lead Agent, the “Agents”) will conduct the Offering on a commercially reasonable efforts basis as the Company’s agents for the Offering in Canada. The Units may also be offered for sale in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and applicable state laws.
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced positive data from its ongoing Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) following bone marrow transplant.
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") is pleased to announce the closing of its previously announced non-brokered private placement (the “Offering”) under which it sold C$787,500 aggregate principal amount of convertible debenture units for an aggregate purchase price of C$750,000 (representing an original issue discount equal to 5% of the purchase price). The convertible debenture units consist of an aggregate of $787,000 principal amount of 10.0% secured convertible debentures (the “Convertible Debentures”) and an aggregate of 12,115,384 common share purchase warrants (each, a “Warrant”). The Convertible Debentures will bear interest from the date of closing at 10.0% per annum, payable quarterly in arrears on the last business day of May, August, November and February of each year commencing May 31, 2019, and will mature on March 6, 2021 (the “Maturity Date”). The Company’s obligations under the Convertible Debentures will be guaranteed by its material subsidiaries, and such guarantee obligations will be secured by substantially all of the assets of such subsidiaries.
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has initiated a food effect study (“Study KAL-07”), as part of its lead product development program evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”). Study KAL-07 is being initiated pursuant to written guidance received from U.S. Food and Drug Administration (the “FDA”). The FDA is requiring that the Company complete a study in healthy volunteers to assess the effect of food intake on the absorption of oral CBD, prior to initiation of a Phase 3 registration study.
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") announced today that it is proceeding with a private placement (the “Offering”) under which it intends to sell C$787,500 aggregate principal amount of convertible debenture units for an aggregate purchase price of C$750,000 (representing an original issue discount equal to 5% of the purchase price). The convertible debenture units will consist of an aggregate of $787,000 principal amount of 10.0% secured convertible debentures (the “Convertible Debentures”) and an aggregate of 12,115,384 common share purchase warrants (each, a “Warrant”). The Convertible Debentures will bear interest from the date of closing at 10.0% per annum, payable quarterly in arrears on the last business day of May, August, November and February of each year commencing May 31, 2019, and will mature two years following the closing of the Offering (the “Maturity Date”).
SAN FRANCISCO and TEL AVIV, Israel, Feb. 26, 2019 -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the.
SAN FRANCISCO, and TEL AVIV, Israel, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today completed certain transactions contemplated by the arrangements reached with the former shareholders of Talent Biotechs Ltd. of Israel (“Talent”) on terms that were previously announced in August 2018. As previously announced in August 2018, the current balance owing to the former Talent shareholders under these milestone payments is US$1,988,620 plus interest, which debt is evidenced by a promissory note maturing July 31, 2019 bearing interest at the rate of 8% per annum. This promissory note has been issued by a subsidiary of the Company and is secured by the rights of Talent as licensee under the Exclusive License Agreement with MOR.
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced additional positive interim data from its ongoing Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) following bone marrow transplant. Kalytera previously announced, on December 20, 2018, that no patients in the Phase 2 clinical study had developed grades 3 or 4 acute GVHD while receiving oral CBD treatment, and that only one patient had developed grade 2 acute GVHD.
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the Company has elected to issue 13,085,677 common shares of the Company (“Common Shares”) to The Salzman Group in payment of invoices issued under the payments agreement announced on June 15, 2018 (the “June 2018 Agreement”). Under the June 2018 Agreement, The Salzman Group and its affiliates provide general and administrative support services, study set-up work for planned studies in connection with use of CBD in treatment of GVHD, and research and development work in connection with Kalytera’s exclusive license of cannabidiol-naproxen conjugates for treatment of pain.
SAN FRANCISCO and TEL AVIV, ISRAEL , Jan. 28, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has granted stock options on January 25, 2019 to certain directors and employees of the Company. The stock options have an exercise price of $0.085 per common share and expire ten years from the date of grant. One third of the options granted will vest on January 25, 2020 and the remaining options will vest in twenty-four (24) equal monthly installments commencing February 2020. Stock options to purchase 1,129,318 common shares of Kalytera were issued to each of Ron Erickson and Jeff Paley, who are independent members of the Company’s board of directors, and stock options to purchase 1,246,092 common shares of Kalytera were issued to Robert Farrell, a director and the Chief Executive Officer of the Company. Stock options to purchase 300,000 common shares of Kalytera were issued to Victoria Rudman, the Company’s Interim Chief Financial Officer, while Drs. Prutchi-Sagiv and Yeshurun were each granted stock options to purchase 600,000 common shares of the Company.
Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. SAN FRANCISCO and TEL AVIV, Israel, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company” or “Kalytera”) is pleased to announce the closing of its private placement previously announced on January 11, 2019 of 3,558,573 common shares of the Company and 3,558,573 common share purchase warrants for aggregate gross proceeds of C$266,893. Alere Financial Partners, a division of Cova Capital Partners LLC, acted as agent and as compensation will receive a cash commission equal to $16,851 and will be issued 204,687 warrants bearing the same terms as those issued in the offering.
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") announced that Echelon Wealth Partners, Inc. (“Echelon”) has initiated research coverage on Kalytera with a speculative "Buy" rating and a one-year price target of $0.30 per share. The Company is pleased with the report and the recommendation, but emphasizes that the views expressed in the report are those of Echelon alone. Echelon is a leading, independent Canadian-owned and operated wealth management and capital markets firm.
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the Company has elected to issue 9,387,831 common shares of the Company (“Common Shares”) to The Salzman Group in payment of invoices issued under the payments agreement with The Salzman Group previously announced on December 7, 2017 (the “December 2017 Agreement”) and the additional payments agreement announced on June 15, 2018 (the “June 2018 Agreement”). Under the December 2017 Agreement, The Salzman Group provides, among other services, clinical study management services in relation to the Phase 2 study evaluating the use of cannabidiol in the prevention of graft versus host disease. Under the June 2018 Agreement, The Salzman Group and its affiliates provide general and administrative support services, study set-up work for planned studies in connection with use of CBD in treatment of GVHD, and research and development work in connection with Kalytera’s exclusive license of cannabidiol-naproxen conjugates for treatment of pain.
Kalytera Therapeutics, Inc. (the “Company” or “Kalytera”) (TSX VENTURE: KALY) (KALTF) announced today that it is proceeding with a private placement under which it intends to sell up to an aggregate of 6,000,000 common shares of the Company (the “Common Shares”) and 6,000,000 common share purchase warrants (the “Warrants”) for aggregate gross proceeds of up to C$450,000 (representing a subscription of C$0.075 per each unit consisting of one Common Share and one Warrant) (the “Offering”). Each Warrant will be exercisable to acquire one Common Share at an exercise price of C$0.10 per Common Share for a period of two years following the Closing Date, subject to customary adjustments in certain events, provided that if, at any time following the date that is four months and one day from the Closing Date, the daily volume weighted average trading price of the Common Shares equals or exceeds C$1.00 for any 10 consecutive trading days, the Company may, on prior written notice, accelerate the expiry date of the Warrants to the date that is 30 days following the date of such notice. Any unexercised Warrants shall thereafter automatically expire.
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced positive interim data from its ongoing Phase 2 clinical study evaluating cannabidiol (“CBD”) for the prevention of acute graft versus host disease (“GVHD”) following bone marrow transplant. GVHD is a life-threatening complication commonly occurring after bone marrow transplant procedures. There are currently no FDA approved therapies for either the prevention or treatment of acute GVHD.
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the Company has elected to issue 10,124,550 common shares of the Company (“Common Shares”) to The Salzman Group in payment of invoices issued under the payments agreement announced on June 15, 2018 (the “June 2018 Agreement”). Under the June 2018 Agreement, The Salzman Group and its affiliates provide general and administrative support services, study set-up work for planned studies in connection with use of CBD in treatment of GVHD, and research and development work in connection with Kalytera’s exclusive license of cannabidiol-naproxen conjugates for treatment of pain. The invoiced amounts to be paid in Common Shares to The Salzman Group total to the amount of US$587,164 (or C$774,528.03 based on the daily average exchange rate for December 3, 2018 published by the Bank of Canada). The number of Common Shares to be issued is based on a deemed issue price of C$0.0765 per Common Share, being 90% of the closing price of the Common Shares on the TSXV on December 3, 2018, the trading day prior to the Company’s election to pay the invoiced amounts in Common Shares. The Common Shares are expected to be issued to The Salzman Group on or about December 5, 2018.
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today reported financial results for the third quarter of 2018. The Company recorded net income of approximately $1.8 million ($0.01 per Common Share) in the third quarter of 2018, compared with a net loss of approximately $1.2 million ($0.01 per Common Share) in the third quarter of 2017. This increase in net income of approximately $3.0 million from third quarter 2017 to third quarter 2018 is mainly due to an offset of $12.9 million recorded in general and administrative expense due to a change in assumptions made in the assessment of the fair value of the Company’s contingent liability relating to the acquisition of Talent Biotechs Ltd. (“Talent”) in 2017, balanced against an increase of approximately $9.9 million in other expenses arising out of impairment to the value of the Talent intellectual property.
Investorideas.com, a leading investor news resource for cannabis stocks releases a snapshot looking at CBD and its future role as a pain treatment in healthcare, and how it is being advocated and embraced by professional athletes. The World Anti-Doping Agency (WADA) officially removed cannabidiol (CBD) from its Prohibited Substances List effective January 1, 2018 and that has opened up a lot of opportunity for athletes looking for more natural pain treatment solutions and companies in the space. In June of this year, The BIG3 basketball league announced they will allow players to use cannabidiol (CBD) as a pain treatment and for recovery.
Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that the Company has elected to issue 3,963,988 common shares of the Company (“Common Shares”) to The Salzman Group in payment of invoices issued under the payments agreement announced on June 15, 2018 (the “June 2018 Agreement”). Under the June 2018 Agreement, The Salzman Group and its affiliates provide general and administrative support services, study set-up work for planned studies in connection with use of CBD in treatment of GVHD, and research and development work in connection with Kalytera’s exclusive license of cannabidiol-naproxen conjugates for treatment of pain. The invoiced amounts to be paid in Common Shares to The Salzman Group total to the amount of US$297,164 (or C$392,434.78 based on the daily average exchange rate for November 9, 2018 published by the Bank of Canada). The number of Common Shares to be issued is based on a deemed issue price of C$0.099 per Common Share, being 90% of the closing price of the Common Shares on the TSXV on November 9, 2018, the trading day prior to the Company’s election to pay the invoiced amounts in Common Shares. The Common Shares are expected to be issued to The Salzman Group on or about the date hereof.